Elicio Therapeutics, Inc. Financials
This page shows Elicio Therapeutics, Inc. (ELTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is still the operating fuel, while cash burn reflects research spending rather than asset-heavy expansion.
In FY2023, operating cash burn of-$32.7M was almost identical to the net loss of-$35.2M , showing the deficit was cash-real rather than mainly accounting. That same pattern persisted in FY2025, with operating cash flow at-$37.0M and financing cash flow at$36.7M ; the cash balance was effectively preserved by new capital rather than operations.
The company looks asset-light: capital spending was just
The balance sheet became less strained short term: the current ratio improved from 1.8x in FY2024 to 2.4x in FY2025. Long-term debt also fell to
Financial Health Signals
Elicio Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Elicio Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
Elicio Therapeutics, Inc. reported a net loss of $39.6M while operations used $37.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Elicio Therapeutics, Inc. reported an operating loss of $37.7M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Elicio Therapeutics, Inc.'s EBITDA was -$37.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.0% from the prior year.
Elicio Therapeutics, Inc. reported -$39.6M in net income in fiscal year 2025. This represents an increase of 23.8% from the prior year.
Elicio Therapeutics, Inc. earned -$2.58 per diluted share (EPS) in fiscal year 2025. This represents an increase of 39.3% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Elicio Therapeutics, Inc. recorded an outflow of $37.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 0.5% from the prior year.
Elicio Therapeutics, Inc. held $18.6M in cash against $9.4M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Elicio Therapeutics, Inc.'s ROE was -2418.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Elicio Therapeutics, Inc. invested $24.9M in research and development in fiscal year 2025. This represents a decrease of 26.0% from the prior year.
Elicio Therapeutics, Inc. invested $16K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 81.6% from the prior year.
Not reported for fiscal year 2025.
ELTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $2.3M-91.9% | $28.3M+883.1% | $2.9M |
| Cost of Revenue | N/A | N/A | N/A | N/A | $0-100.0% | $433K-63.6% | $1.2M |
| Gross Profit | N/A | N/A | N/A | N/A | $2.3M-91.7% | $27.9M+1549.6% | $1.7M |
| R&D Expenses | N/A | $24.9M-26.0% | $33.7M+41.1% | $23.8M+31.7% | $18.1M-62.8% | $48.7M+24.9% | $39.0M |
| SG&A Expenses | N/A | $12.8M+13.1% | $11.3M-4.8% | $11.9M+111.3% | $5.6M-69.5% | $18.5M+2.8% | $18.0M |
| Operating Income | N/A | -$37.7M+16.2% | -$45.0M-25.9% | -$35.7M-50.6% | -$23.7M+39.6% | -$39.3M+28.9% | -$55.3M |
| Interest Expense | N/A | $1.1M+149.0% | $455K-57.0% | $1.1M-70.6% | $3.6M+294.7% | -$1.8M+79.1% | -$8.8M |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$39.6M+23.8% | -$51.9M-47.5% | -$35.2M-24.8% | -$28.2M+48.3% | -$54.6M+31.9% | -$80.1M |
| EPS (Diluted) | — | -$2.58+39.3% | -$4.25 | -$6.96 | -$89.27 | -$1.93 | -$5.43 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ELTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $25.9M-8.2% | $28.2M+3.8% | $27.1M+19.8% | $22.7M-76.5% | $96.5M+103.8% | $47.3M |
| Current Assets | $19.3M-6.7% | $20.7M+26.6% | $16.3M+52.5% | $10.7M-88.3% | $91.2M+115.7% | $42.3M |
| Cash & Equivalents | $18.6M+5.4% | $17.6M+36.6% | $12.9M+109.5% | $6.2M-93.1% | $88.8M+156.5% | $34.6M |
| Total Liabilities | $24.2M-38.7% | $39.5M+150.4% | $15.8M-87.4% | $124.8M-27.0% | $171.0M+24.1% | $137.8M |
| Current Liabilities | $8.1M-29.6% | $11.5M+18.1% | $9.8M+42.0% | $6.9M-39.2% | $11.3M-89.5% | $107.4M |
| Long-Term Debt | $9.4M-53.0% | $20.0M | N/A | N/A | $0-100.0% | $635K |
| Total Equity | $1.6M+114.5% | -$11.3M-199.5% | $11.4M+111.1% | -$102.1M-37.0% | -$74.5M+17.6% | -$90.4M |
| Retained Earnings | -$233.7M-20.4% | -$194.1M-36.5% | -$142.2M-32.9% | -$107.0M+50.3% | -$215.1M-34.0% | -$160.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
ELTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$37.7M | -$37.0M+0.3% | -$37.1M-13.4% | -$32.7M-47.4% | -$22.2M+57.9% | -$52.6M-130.0% | -$22.9M |
| Capital Expenditures | N/A | $16K-81.6% | $87K+31.8% | $66K-89.9% | $654K+71.2% | $382K+831.7% | $41K |
| Free Cash Flow | N/A | -$37.0M+0.5% | -$37.2M-13.4% | -$32.8M-43.5% | -$22.8M+56.9% | -$53.0M-131.3% | -$22.9M |
| Investing Cash Flow | N/A | -$16K+81.0% | -$84K-162.5% | -$32K+95.1% | -$654K-71.2% | -$382K-831.7% | -$41K |
| Financing Cash Flow | $39.0M | $36.7M-13.3% | $42.3M+9.6% | $38.6M+82.1% | $21.2M-80.2% | $107.2M+104.5% | $52.4M |
| Share Buybacks | N/A | N/A | $0-100.0% | $150K | $0 | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ELTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | 100.0%+1.5pp | 98.5%+39.8pp | 58.7% |
| Operating Margin | N/A | N/A | N/A | -1031.4% | -138.8% | -1919.2% |
| Net Margin | N/A | N/A | N/A | -1225.9% | -192.8% | -2781.5% |
| Return on Equity | -2418.8% | N/A | -309.5% | N/A | N/A | N/A |
| Return on Assets | -153.0%+31.2pp | -184.2%-54.5pp | -129.7%-5.2pp | -124.5%-67.9pp | -56.5%+112.7pp | -169.2% |
| Current Ratio | 2.38+0.6x | 1.80+0.1x | 1.68+0.1x | 1.56-6.5x | 8.08+7.7x | 0.39 |
| Debt-to-Equity | 5.75 | N/A | 1.39 | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | -992.3% | -187.3% | -796.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Elicio Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Elicio Therapeutics, Inc. profitable?
No, Elicio Therapeutics, Inc. (ELTX) reported a net income of -$39.6M in fiscal year 2025.
What is Elicio Therapeutics, Inc.'s EBITDA?
Elicio Therapeutics, Inc. (ELTX) had EBITDA of -$37.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Elicio Therapeutics, Inc. have?
As of fiscal year 2025, Elicio Therapeutics, Inc. (ELTX) had $18.6M in cash and equivalents against $9.4M in long-term debt.
What is Elicio Therapeutics, Inc.'s return on equity (ROE)?
Elicio Therapeutics, Inc. (ELTX) has a return on equity of -2418.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Elicio Therapeutics, Inc.'s free cash flow?
Elicio Therapeutics, Inc. (ELTX) recorded an outflow of $37.0M in free cash flow during fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Elicio Therapeutics, Inc.'s operating cash flow?
Elicio Therapeutics, Inc. (ELTX) recorded an outflow of $37.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Elicio Therapeutics, Inc.'s total assets?
Elicio Therapeutics, Inc. (ELTX) had $25.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Elicio Therapeutics, Inc.'s capital expenditures?
Elicio Therapeutics, Inc. (ELTX) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Elicio Therapeutics, Inc. spend on research and development?
Elicio Therapeutics, Inc. (ELTX) invested $24.9M in research and development during fiscal year 2025.
What is Elicio Therapeutics, Inc.'s current ratio?
Elicio Therapeutics, Inc. (ELTX) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.
What is Elicio Therapeutics, Inc.'s debt-to-equity ratio?
Elicio Therapeutics, Inc. (ELTX) had a debt-to-equity ratio of 5.75 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Elicio Therapeutics, Inc.'s return on assets (ROA)?
Elicio Therapeutics, Inc. (ELTX) had a return on assets of -153.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Elicio Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Elicio Therapeutics, Inc. (ELTX) had $18.6M in cash against an annual operating cash burn of $37.0M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Elicio Therapeutics, Inc.'s Piotroski F-Score?
Elicio Therapeutics, Inc. (ELTX) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Elicio Therapeutics, Inc.'s earnings high quality?
Elicio Therapeutics, Inc. (ELTX) reported a net loss of $39.6M while operations used $37.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Elicio Therapeutics, Inc. cover its interest payments?
Elicio Therapeutics, Inc. (ELTX) reported an operating loss of $37.7M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.